Magnite Rallies on Google Antitrust Remedies; Target Raised to $32

What happened

Magnite shares jumped 5% after Craig-Hallum lifted its price target to $32, citing the unsealed remedies opinion in the DOJ's antitrust case against Google, which could level the playing field for independent sell-side platforms. PubMatic also rose 6%, while The Trade Desk barely moved, indicating the boost is specific to supply-side sellers that compete directly with Google's ad exchange. The market is pricing in potential benefits from Google being forced to alter auction dynamics, but details of the remedies remain unclear. Magnite's fundamentals remain solid, with 2024 GAAP profitability and CTV leadership, but valuation at ~56x TTM P/E and rising interest costs warrant caution. This news may shift sentiment, but the long-term impact depends on actual enforcement and structural changes.

Implication

While the unsealed remedies opinion suggests a more competitive ad tech landscape, Magnite's ability to capture incremental share depends on execution and the extent of Google's mandated changes. The stock's jump reflects optimism, but at ~56x TTM P/E, much is already priced in. Rising interest costs and a slowdown in 1H25 operating cash flow remain concerns. We maintain our HOLD/NEUTRAL stance and would look for sustained CTV growth and SPO wins before turning more constructive. Should remedies be enforced effectively, Magnite could see expanded auction access, but competitive dynamics may also intensify.

Thesis delta

The news does not fundamentally change our neutral view, but it introduces a potential positive catalyst from regulatory action. While it may reduce Google's dominance in ad auctions, the implementation timeline and competitive response are uncertain. Therefore, we keep our thesis unchanged but note increased upside optionality if remedies are enforced effectively.